Research projects

​The project will apply a multidisciplinary approach combining studies in cellular and animal models to investigate if ''cell free'' purified AD-MSCs exosome treatment can protect and regenerate ß cell.

​This study is part of The RESET study performed at SDCC in the Pathophysiology & Prevention team in the Clinical Epidemiology group.

​​The gene encoding the lysosomal cysteine protease cathepsin H (CTSH) is a type 1 diabetes (T1D) candidate gene located at the susceptibility locus on chromosome 15q25.1. The project aims at understanding the roles of CTSH and other cathepsins for beta cell function and T1D risk.

In this study, we will investigate the antidiabetic effects of the drug fenofibrate in newly onset T1D. The study is designed as a randomized, double-blinded placebo-controlled clinical trial with 58 newly diagnosed T1D patients.    

​INNODIA (an innovative approach towards understanding and arresting type 1 diabetes)is an international consortium consisting of academic institutions including SDCC, clinics, patient organizations, partners and enterprises.

​​The project seeks to identify risk metabolomic profiles for autoimmunity and type 1 diabetes. By further investigating the relationship of these metabolomic profiles with other established genetic and environmental risk factors for type 1 diabetes, we hope to contribute to the unraveling of this complex immunologic/metabolic disease and highlight potential new therapeutic targets.

​​The gene encoding Src kinase-associated phosphoprotein 2 (SKAP2) located on Chr 7 is a type 1 diabetes (T1D) candidate gene. The project seeks to clarify if SKAP2 affects T1D risk by modulating beta cell fragility.